196 related articles for article (PubMed ID: 27139150)
21. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
22. Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium.
Garg K; Soslow RA
Adv Anat Pathol; 2012 Jan; 19(1):1-10. PubMed ID: 22156830
[TBL] [Abstract][Full Text] [Related]
23. Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases.
Culton LK; Deavers MT; Silva EG; Liu J; Malpica A
Am J Surg Pathol; 2006 Jul; 30(7):844-9. PubMed ID: 16819326
[TBL] [Abstract][Full Text] [Related]
24. Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.
Park JY; Nam JH; Kim YT; Kim YM; Kim JH; Kim DY; Sohn I; Lee SW; Sung CO; Kim KR
Virchows Arch; 2013 Mar; 462(3):289-96. PubMed ID: 23417747
[TBL] [Abstract][Full Text] [Related]
25. [New features in the 2014 WHO classification of uterine neoplasms].
Lax SF
Pathologe; 2016 Nov; 37(6):500-511. PubMed ID: 27738815
[TBL] [Abstract][Full Text] [Related]
26. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility.
Fadare O; Desouki MM; Gwin K; Hanley KZ; Jarboe EA; Liang SX; Quick CM; Zheng W; Parkash V; Hecht JL
Am J Surg Pathol; 2014 Feb; 38(2):189-96. PubMed ID: 24145649
[TBL] [Abstract][Full Text] [Related]
27. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma.
Scholten AN; Smit VT; Beerman H; van Putten WL; Creutzberg CL
Cancer; 2004 Feb; 100(4):764-72. PubMed ID: 14770433
[TBL] [Abstract][Full Text] [Related]
29. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.
Soslow RA; Tornos C; Park KJ; Malpica A; Matias-Guiu X; Oliva E; Parkash V; Carlson J; McCluggage WG; Gilks CB
Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S64-S74. PubMed ID: 30550484
[TBL] [Abstract][Full Text] [Related]
30. The reproducibility of a binary tumor grading system for uterine endometrial endometrioid carcinoma, compared with FIGO system and nuclear grading.
Sagae S; Saito T; Satoh M; Ikeda T; Kimura S; Mori M; Sato N; Kudo R
Oncology; 2004; 67(5-6):344-50. PubMed ID: 15713989
[TBL] [Abstract][Full Text] [Related]
31. Precursors of endometrial clear cell carcinoma.
Fadare O; Liang SX; Ulukus EC; Chambers SK; Zheng W
Am J Surg Pathol; 2006 Dec; 30(12):1519-30. PubMed ID: 17122507
[TBL] [Abstract][Full Text] [Related]
32. Undifferentiated carcinoma of the endometrium.
Altrabulsi B; Malpica A; Deavers MT; Bodurka DC; Broaddus R; Silva EG
Am J Surg Pathol; 2005 Oct; 29(10):1316-21. PubMed ID: 16160474
[TBL] [Abstract][Full Text] [Related]
33. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
Zhang L; Liu Y; Hao S; Woda BA; Lu D
Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
[TBL] [Abstract][Full Text] [Related]
34. The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
Hagemann IS; Deng W; Zaino RJ; Powell MA; Gunderson C; Cosgrove C; Mathews C; Pearl ML; Waggoner S; Ghebre R; Lele S; Guntupalli S; Secord AA; Ioffe O; Park K; Rasty G; Singh M; Soslow R; Creasman W; Mutch DG
Gynecol Oncol; 2021 Mar; 160(3):660-668. PubMed ID: 33423806
[TBL] [Abstract][Full Text] [Related]
35. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
37. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
39. Determining the inter- and intraobserver reproducibility of the diagnosis of endometrial hyperplasia subgroups and well-differentiated endometrioid carcinoma in endometrial curettage specimens.
Izadi-Mood N; Khaniki M; Irvanloo G; Ahmadi SA; Hayeri H; Meysamie A
Arch Iran Med; 2009 Jul; 12(4):377-82. PubMed ID: 19566355
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma.
Fadare O; Liang SX
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):580-7. PubMed ID: 22495362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
